Search results
Showing 136 to 150 of 177 results for pembrolizumab
Awaiting development Reference number: GID-TA11343 Expected publication date: TBC
Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults.
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
In development Reference number: GID-TA11406 Expected publication date: TBC
Discontinued Reference number: GID-TA10234
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Discontinued Reference number: GID-TA10848
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Discontinued Reference number: GID-TA11289
Discontinued Reference number: GID-TA10202
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
In development Reference number: GID-TA11008 Expected publication date: TBC
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)
This guidance has been updated and replaced by NICE technology appraisal guidance 766.